Swiss drugmaker Debiopharm has presented results from a Phase IIa study with Debio 025, a selective cyclophilin inhibitor with a potent anti-hepatitis C effect at the annual meeting of the European Association for the Study of the Liver, in Copenhagen, Denmark.
The Phase IIa study investigated the efficacy and safety of Debio 025 in combination with Peg-interferon alpha 2a and ribavirin in previously null-responder genotype 1 HCV patients. Results demonstrated that Debio 025 at doses of 400mg (with initial loading) and 800mg daily for 29 days showed a statistically-significant reduction of HCV RNA of respectively -1.96 log (-98.9%) and -2.38 log (-99.5%) when co-administered with Peg-IFN alpha-2a and ribavirin in previous null responders.
"These results in patients who are highly unlikely to respond to retreatment with an interferon-based regimen, are very important to us, as they confirm that Debio 025 is a potent anti-HCV agent," said Rolland-Yves Mauvernay, founder of Debiopharm.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze